Suggested remit: To appraise the clinical and cost effectiveness of avatrombopag within its marketing authorisation for treating thrombocytopenia in people with chronic liver disease needing elective surgery.
Status Proposed
Process STA 2018
ID number 1105

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
29 May 2018 - 26 June 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance